SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQs sharp after-hours drop drew attention as traders linked the move to the FAAs nationwide ground stop after communications problems, while speculation about a cyberattack or AI involvement remained unverified. The discussion also reflected wider pressure on tech and AI stocks tied to uncertainty around Nvidia, with traders divided between seeing the selloff as an overreaction and expecting further weakness.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summits FDA review of ivonescimab for EGFR-mutated lung cancer is driving a binary-outcome debate over approval versus a possible rejection or request for more evidence. Bulls point to strong progression-free-survival results and encouraging survival trends, while bears focus on the FDAs stated need for statistically significant overall-survival evidence; recent weakness has also prompted speculation about a negative outcome, though traders say price action alone is not proof.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The upcoming Phase 3 REGAL trial readout for SELLASs AML treatment GPS dominates discussion, with traders focused on the binary clinical catalyst. Bulls anticipate strong results, while skeptics cite the stocks sharp volatility and warn of failure risk or a sell-the-news reaction; claims of short-term manipulation remain speculation.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians volatile, weak share performance is driving debate, with traders blaming heavy short-selling and persistent selling pressure while bulls point to improving deliveries, the R2 ramp, and upcoming autonomy developments. Sentiment remains split between concern over cash burn and execution and hopes that the companys growth initiatives can improve its outlook.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

Reports of an FAA nationwide ground stop tied to air-traffic-control communications problems are drawing attention to AAL, with traders discussing possible departure delays and rerouting. Some characterize the disruption as brief, while speculation about its cause remains unverified.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Reported takeover discussions involving Silver Lake and Saudi Arabias PIF are driving speculation, though no deal is confirmed; traders disagree over whether a potential offer would undervalue Unity. The interest is reinforced by strong quarterly results and the companys first GAAP-profitable quarter, with bullish call activity and breakout chatter alongside skepticism about the rally.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius selloff is being tied to its earnings outlook and delays in activating third-party data-center capacity, which push expected revenue into a later period and have prompted analyst price-target cuts. Traders are divided between viewing the execution and heavy-capex concerns as a reason for further downside and treating the drop as an overreaction, with broader weakness in AI and neocloud stocks adding pressure.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novos stronger-than-expected quarterly results and raised full-year outlook, driven largely by demand for its Wegovy pill, have fueled renewed buying interest. Traders are debating whether the oral drugs momentum can support a sustained recovery amid Lilly competition and concerns about Novos execution.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs abrupt departure is driving debate over Nvidias leadership transition, with traders speculating about his return and possible successors while others worry about leadership uncertainty and scrutiny of chip exports to China. Bulls argue Nvidias business remains strong and point to earnings, while bears see unresolved risks weighing on confidence.

HawKeye 360, Inc. engages in the provision of defense technology. It offers spectrum monitoring, maritime intelligence, air defence radar monitoring, GNSS interference detection, and communications mapping. Its costumers include a wide range of commercial, government and international entities. The company was founded by Charles T. Clancy, Robert G. McGwier, Chris DeMay and John Serafini in 2015 and is headquartered in Herndon, VA.

HawkEye 360 Inc.

HAWK is drawing attention after reporting record third-quarter revenue and raising its full-year outlook, with traders also highlighting international growth, contract demand, and plans for lower-cost satellites. The community reaction is broadly bullish on the results and rally, though claims of institutional accumulation and further upside remain speculative.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Can BMY Sustain Growth in Its Cardiovascular Franchise?

Bristol Myers Squibb is expanding Camzyos??? reach, benefiting from Eliquis??? strong sales and advancing milvexian to drive cardiovascular growth.

FDA Decision Watch: Summit’s Lung Cancer Drug, Cytokinetics’ Heart Therapy And Teva’s Igalmi In Spotlight This Week

Equity

The FDA is set to announce its verdict on three closely watched therapies this week, ahead of a busy month which includes a decision on Capricor Therapeutics’ Deramiocel.


Cytokinetics (CYTK) Q3 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Cytokinetics (CYTK) Reports Q3 Loss, Beats Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of +8.67% and +10.57%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Will Alector (ALEC) Report Negative Q3 Earnings? What You Should Know

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?

Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?

Cytokinetics' Myqorzo gains commercial traction with growing prescriptions, international launches and promising clinical data that could expand its market opportunity.

Cytokinetics Q2 2026 Earnings Call: Complete Transcript

On Thursday, Cytokinetics (NASDAQ:CYTK) discussed second-quarter financial results during its earnings call. The full transcript is provided below.
This content is powered by Benzinga APIs. For comprehensive financialread more...

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist 

JNJ reports third-quarter results on Tuesday, and Koyfin analysts expect modest revenue growth and lower earnings.

Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?

Bristol Myers' Camzyos gains a broader FDA label and strong sales growth, while emerging competitors and pipeline setbacks shape its cardiovascular outlook.

• Reported GAAP EPS of -$1.37 up 46.27% YoY
• Reported revenue of $47.56M up 2351.55% YoY
• Cytokinetics reaffirmed full-year 2026 guidance for GAAP combined R&D and SG&A expense of $860M to $890M and non-cash stock-based compensation expense of $140M to $130M.

Cytokinetics Q3 SG&A and R&D expenses increased, it reported a $190.1M net loss and lower cash balances, and it identifies cardiac-myosin competition and market acceptance as risks.

Cytokinetics reported $44.5M in MYQORZO revenue and a broadening prescriber base, received international authorizations, and reported positive ACACIA-HCM Phase 3 results, with regulatory submissions planned.

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Cytokinetics Inc

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>Summit’s Ivonescimab faces a critical FDA decision after its Phase 3 trial failed to show a statistically significant survival benefit in its primary analysis.</li><li>Cytokinetics seeks to add head-to-head clinical trial results to the label of its already-approved heart disease treatment, Myqorzo.</li><li>Teva recently acquired worldwide rights to IGALMI from BioXcel Therapeutics for $57.5 million.</li></ul><p>The U.S. Food and Drug Administration (FDA) is set to decide on three major drug applications this week, covering treatments for lung cancer, heart disease, and acute agitation associated with psychiatric disorders</p><p>In what could potentially be a busy month, the regulator will announce its decision on therapies by <a class="mention" data-mention="$SMMT" data-symbol-id="SMMT" href="https://stocktwits.com/symbol/SMMT" target="_blank">Summit Therapeutics</a> (SMMT), Cytokinetics (CYTK), and Teva Pharmaceutical Industries (TEVA), after <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-u-s-fda-approval-of-rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-as-first-and-only-dual-targeted-therapy-for-advanced-head-and-neck-cancer">approving</a> Johnson &amp; Johnson’s (JNJ) Rybrevant Faspro to treat adults with recurrent or metastatic head and neck squamous cell carcinoma last week.</p><p><img src="https://news.stocktwits-cdn.com/d_Go5c_pdufa_this_week_cdf6a9af9c.png" alt="dGo5c-pdufa-this-week-.png"></p><h2 class="st-heading-2">Summit Awaits FDA Decision On Lung Cancer Drug</h2><p>Summit Therapeutics’ Ivonescimab is a cancer treatment developed in partnership with China-based Akeso, for patients with advanced non-small cell lung cancer (NSCLC) carrying EGFR mutations whose disease has progressed following targeted therapy. Ivonescimab is designed to block two proteins, PD-1 and VEGF, that lead to cancer cell growth.</p><p>The Phase 3 Harmoni trial met its primary goal of improving progression-free survival, though the study’s initial analysis failed to show a statistically significant improvement in overall survival.</p><p>Last week, Summit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Third-Quarter-and-Nine-Months-Ended-September-30-2026/">said</a> updated results from the trial showed a 24% reduction in the estimated risk of death with Ivonescimab plus chemotherapy compared with chemotherapy alone.</p><h2 class="st-heading-2">Cytokinetics Seeks Label Update For Myqorzo</h2><p>Cytokinetics is awaiting an FDA decision on whether it can add results from its Phase 3 Maple-HCM trial to the prescribing information for Myqorzo, an already-approved treatment for a heart condition that restricts blood flow.</p><p>The Maple-HCM trial showed that patients receiving the drug achieved significantly greater improvements in exercise capacity after 24 weeks compared with those receiving Metoprolol, a commonly used heart medication. According to the company, Myqorzo&nbsp;improved peak oxygen consumption by an additional 2.3 ml per kilogram per minute compared with metoprolol.</p><h2 class="st-heading-2">Teva Eyes Igalmi Approval For At-Home Treatment</h2><p>The FDA is set to decide on the expanded use of Igalmi to treat acute agitation associated with schizophrenia or bipolar disorder for adults at home.</p><p>Igalmi is already approved for use under medical supervision, and the proposed expansion would allow patients to administer the treatment outside healthcare facilities.</p><p>The application is supported by the Phase 3 Serenity At-Home trial, which met its primary safety objective. Exploratory analyses also showed reductions in agitation symptoms compared with placebo.</p><p>Last month, Teva <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.tevausa.com/news-and-media/press-releases/teva-acquires-worldwide-rights-to-bxcl501-further-expanding-innovative-neuroscience-pipeline/">announced</a> that it had acquired worldwide rights to Igalmi from BioXcel Therapeutics following the latter’s bankruptcy proceedings. Under the agreement, Teva paid $57.5 million upfront, while BioXcel’s estate remains eligible for up to $67.5 million in additional payments tied to FDA approval, along with potential commercial milestones.</p><h2 class="st-heading-2">Retail’s Take On CYTK, SMMT And TEVA</h2><p>Retail sentiment for CYTK on Stocktwits remained ‘extremely bullish’ over the past 24 hours, ‘bullish’ for TEVA, while sentiment turned ‘neutral’ for SMMT from ‘bullish.’</p><p><img src="https://news.stocktwits-cdn.com/FDA_9cc50d6197.png" alt="FDA.png"></p><p>Teva has been the best-performing stock in the cohort this year, surging 36.7%, while Cytokinetics and Summit Therapeutics have declined 13% and 6.8%, respectively.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the FDA (United States Food and Drug Administration) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

The FDA is set to announce its verdict on three closely watched therapies this week, ahead of a busy month which includes a decision on Capricor Therapeutics’ Deramiocel.

Teva- Pharmaceutical Industries Ltd. - ADR

SPDR S&P Biotech ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	-$1.41	--	--	N/A
Q3 '26	-$1.44	-$1.37	4.70%	BEAT
Q2 '26	-$1.63	-$1.50	7.88%	BEAT
Q1 '26	-$1.65	-$1.67	-1.07%	MISSED
Q4 '25	-$1.56	-$1.50	4.12%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

CYTK Earnings

Latest Earnings Results: Q3 '26

Historical Earnings